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Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes CoronaVirus Disease 2019 (COVID-
19), has resulted in a worldwide pandemic and currently represents a major public health crisis. It has caused outbreaks of 
illness through person-to-person transmission of the virus mainly via close contacts, and droplets produced by an infected 
person’s cough or sneeze. Aerosolised inhaled therapy is the mainstay for treating obstructive airway diseases at home and 
in healthcare settings, but there is heightened particular concern about the potential risk for transmission of SARS-CoV-2 in 
the form of aerosolised respiratory droplets during the nebulised treatment of patients with COVID-19. As a consequence 
of this concern, the use of hand-held inhalers, especially pressurised metered dose inhalers, has risen considerably as an 
alternative to nebulisers, and this switch has led to inadequate supplies of inhalers in some countries. However, there is no 
evidence supporting an increased risk of viral transmission during nebulisation in COVID-19 patients. Furthermore, some 
patients may be unable to adequately use their new device and may not benefit fully from the switch to treatment via hand-held 
inhalers. Thus, there is no compelling reason to alter aerosol delivery devices for patients with established nebuliser-based 
regimens. The purpose of this paper is to discuss the current evidence and understanding of the use of aerosolised inhaled 
therapies during the SARS-CoV-2 pandemic and to provide some guidance on the measures to be taken to minimise the risk 
of transmitting infection, if any, during aerosol therapies.
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The Coronavirus disease 2019 (COVID-19) is a worldwide 
pandemic caused by the highly contagious novel severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
[1]. The latter belongs to the same class of coronaviruses 
that previously resulted in SARS and the Middle East Res-
piratory Syndrome, both of which infected many health care 
professionals in the course of providing patient care [1]. The 
SARS-CoV-2 virus is primarily transmitted through contact 
routes and dispersion of bio-aerosols from the patient [2]. 
Bio-aerosols are defined as aerosols or particulate and matter 
of animal, plant or microbial origin with a range from 0.1 
to > 100 µm in diameter [3], that can contain viruses, bacte-
ria, fungi, and are generated by infected persons when they 
cough, sneeze, talk, sing, or breathe [2]. They can land in 
the mouth, nose, or eyes of those in proximity, and they have 
the potential to be inhaled into the lungs. However, larger 
droplets in the cloud produced by coughing and sneezing 
settle quickly on surfaces around the infected subject, where 
they could be infectious by contact for several days [2]. The 
respiratory droplets evaporate to form smaller droplet nuclei 
that carry infectious agents, remain suspended in air, and 
transported over longer distance by airflow are highly res-
pirable [2].
National and international guidelines recommend bio-
aerosol and contact precautions for those caring for COVID-
19 patients in ambulatory and acute care settings [1, 4–6], 
particularly during aerosol generating procedures, such as 
lung function and challenge testing, bronchoscopy, nebu-
lised treatment, non-invasive ventilation, endotracheal 
intubation, placing patients into prone position, discon-
necting the patient from the ventilator, tracheotomy, and 
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cardiopulmonary resuscitation [7]. These procedures can 
result in the release of bio-aerosols from the respiratory 
tract when treating someone who is suspected or known to 
be suffering from an infectious agent transmitted wholly or 
partly by the airborne or droplet route [7]. Despite the lack 
of evidence, there is currently a heightened concern regard-
ing the potential risk of transmission of SARS-CoV-2 in the 
form of aerosolised respiratory droplets from patients with 
COVID-19 undergoing nebulised treatment [8]. Further-
more, while some guidelines [9, 10] have advised against 
the use of nebuliser treatment unless absolutely necessary, 
others [5, 11] have recommended the continued use of nebu-
lised treatment when applicable.
This intense debate with diametrically opposed opinions 
may have induced confusion and mis-interpretation among 
doctors thus encouraging them to avoid aerosol therapy in 
patients with COVID-19 and obstructive airway diseases 
treated at home, or to switch patients from nebulised thera-
pies to portable inhalers. It seems worth recalling that a sud-
den switch to hand-held inhalers, particularly to pressurised 
metered-dose inhalers (pMDIs), may result in unintended 
consequences for some patients who may be unable to ade-
quately use their new devices or benefit fully from treatment 
delivered by portable inhalers [12]
The present paper aims at providing guidance to phy-
sicians on aerosol therapies for the treatment of obstruc-
tive airway diseases in hospital or home settings during the 
SARS-CoV-2 pandemic, and, based on all current available 
information, illustrating measures to be taken to minimise 
the hypothetical risk of infection.
Aerosol delivery systems and the risk 
of infection transmission
Pressurised metered-dose inhalers, dry powder inhalers 
(DPIs), soft-mist inhalers (SMIs), and nebulisers are aerosol 
delivery systems used for administration of inhaled therapies 
to treat obstructive airway diseases such as asthma or chronic 
obstructive pulmonary disease [13]. Each of these delivery 
systems has advantages and limitations [13], as well as risks 
for device contamination [14–16] (Table 1). Although there 
is no ranking system that assesses the risk of transmission 
with various aerosol delivery devices, the rationale behind 
such an evaluation system could be the treatment time, the 
amount of emitted dose and aerosol mass generated by the 
device during aerosol therapy, and also the design of the 
device impacting towards the risk of contamination during 
device preparation, cleaning and its maintenance [2]. By 
design, the drug is enclosed in portable inhalers (i.e. pMDIs, 
DPIs, and SMIs); thus, they are hard to contaminate and 
the risk for viral transmission may be lower than nebulisers 
which are characterised by open medication reservoirs [15]. 
However, without cleaning the mouthpiece of portable inhal-
ers, deposits could on the inner side of the mouthpiece, thus 
facilitating the growth of micro-organisms [16]. Bacterial 
Table 1  Risk of device contamination and suggestions for safe delivery of aerosolised medications during COVID-19 pandemic
pMDI pressurised metered-dose inhaler, VHC valved-holding chamber, DPI dry powder inhaler, SMI soft mist inhaler
Device Risk of con-
tamination
Suggestions for hand-held inhalers
pMDI Low Prefer the use pMDI in conjunction with a spacer or a VHC instead of the pMDI only
Use a spacer or a VHC with a mouthpiece instead of a face mask;
Train the patient to exhale into the spacer or the VHC to minimise exhaled aerosol dispersion to the environment;
Clean and disinfect the spacer or the VHC according to the manufacturer’s guidelines;
Do not share pMDIs, spacers or VHCs with multiple patients;








Nebulisers High Wash hands and put fresh gloves before filling the nebuliser reservoir and administering treatments;
Ensure device is clean;
Avoid nebulisation in the presence of other people;
Carry out nebulisation near open windows or areas with adequate ventilation;
Ensure proper protective equipment for bystanders or health care personnel
Close the door while nebulisation is being undertaken;
Prefer a mouthpiece instead of a facemask
Prefer vibrating mesh over jet nebulisers;
Attach a filter to the expiratory port of the nebuliser
Rinse the nebuliser cup with distilled or sterile water
Keep the reservoir cap of mesh nebuliser closed after use;
Clean and disinfect the nebuliser according to the manufacturer’s guidelines
Clean the surface and areas of nebulisation
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contamination is common in uncleaned spacer devices used 
in the home setting [14]. Furthermore, the forceful inspira-
tions required to aerosolise the medication from DPIs may 
cause cough [15] thus increasing the distance of exhaled air 
dispersion and the risk of viral transmission in the era of 
COVID-19. Therefore, some authors [15] recommend cau-
tion with the use of DPIs in patients with coughing and air-
way irritation. In summary, although there are no studies that 
have compared the risk of infection transmission between 
different portable inhalers or between portable inhalers and 
nebulisers, there appear to be a limited concern that portable 
inhalers increase SARS-CoV-2 transmission provided that 
the patient can use the device correctly.
Nebulisers are frequently used in hospital setting for 
treating acute asthma or COPD exacebations and at home in 
elderly patients unable to handle portable inhalers correctly 
[13]. It is far more appropriate to refer to the “nebuliser sys-
tem” in its entirety [13] in which several components, other 
than the device itself, play a significant role in influencing 
aerosol delivery and the potential for microbial transmission 
[14]. Among the most influential are the compressor or line 
feed applied to the nebuliser, the volume fill, the residual 
volume, the driving gas flow, and the use of either a face-
mask or mouthpiece. Each of these significantly affects the 
total drug amount received by the patients during therapy, 
the rate of nebulized aerosol output, and the particle size 
distribution. If any component of the nebuliser system is 
replaced by another, then the nebuliser system has changed 
and the aerosol output characteristics will have been signifi-
cantly altered [13]. At present, the evidence about the risk of 
viral transmission through aerosols generated by nebulisers 
is limited [17]. Aerosols generated by a nebuliser are derived 
from a medication solution that is not a bio-aerosol as that 
generated during coughing or sneezing [2]. However, nebu-
lisers generate fugitive emissions from the device during 
the exhalation phase of the patient’s breath [15, 18]. The 
particle size of these fugitive emissions varies from 0.86 
to 1.43 μm and ~ 50% of the generated aerosol is fugitive 
aerosol that remains suspended in the indoor environment 
for several hours [18]. Theoretically, a nebuliser could be 
considered as a fomite, and the risk of viral transmission 
with nebuliser therapies could be largely attributable to 
risk of contamination of the device itself. To investigate the 
hypothesis of virus spread during nebulisation, Tang and 
co-workers [19] simulated a spontaneously breathing adult 
patient with a heated manikin receiving nebulised therapy 
with a jet nebulizer and a facemask. Using a live-attenuated 
influenza vaccine as a surrogate virus tracer, the authors 
found that air samples obtained from three separate locations 
indicated 612 viruses per litre near the head, 174 viruses 
per litre near the abdomen, and 118 viruses per litre near 
the feet. These findings aerosols spreading at decreasing 
concentration with increasing distance from the head of the 
patient [19]. However, it is worth noting that these findings 
were obtained under strict laboratory conditions (fixed tidal 
volume, respiratory rate and exhalation flow, use of distilled 
water) that may not reflect what happen in a real-life setting. 
A retrospective pooled analysis on the risk of SARS-CoV 
transmission to health care professionals with various aero-
sol generating procedures showed that the risk of infection 
to health care professionals increased by 6.6 times with intu-
bation, as opposed to 0.9 times with the use of nebulisers 
[7]. Unlike other aerosol generating procedures that carry 
contaminated particles derived from patients, the medica-
tion in the nebuliser is considered a non-patient source that 
might not generate bio-aerosols carrying pathogens, unless 
the nebuliser is contaminated [17]. Direct comparisons 
between different nebuliser types on the potential risk of 
microbial transmission are lacking, although some may be 
at greater risk than other. For example, jet nebulisers that 
are open to and positioned below the gas pathway could be 
contaminated by patient’s secretions when they are directly 
connected to the patient interface through a mouthpiece or 
an endotracheal tube [17]. In contrast, by design vibrating 
mesh nebulisers generate aerosols via mesh plates that sepa-
rate the medication from the patient interface [2]. In addi-
tion, mesh nebulisers have less residual volume (< 0.5 mL) 
at the end of nebulisation than jet nebulisers (about 2 mL) 
[13], which may create a less hospitable environment for 
micro-organisms. Therefore, vibrating mesh nebulisers 
could be preferred over jet nebulisers for aerosol therapies, 
although they need careful hygiene techniques as those of 
jet nebulisers.
Independent of the nebuliser type used, a risk of bio-
aerosol dispersion exists in case of contamination of the 
reservoir during medication loading process, which need to 
be performed using aseptic techniques. In suitable patients, a 
mouthpiece should be preferred over a facemask to improve 
treatment efficiency and reduce fugitive emissions because 
a mouthpiece does not force aerosols out of the interface 
during therapy [17]. Furthermore, placing a HEPA filter air 
cleaning system in the nebuliser’s outlet in combination with 
a demistifier tent has been found to reduce fugitive emis-
sions and exposure of health care professionals to aerosol 
medications [20]. Similarly, placing a filter in the expiratory 
limb of a ventilator circuit reduced escape of aerosols [11], 
thereby reducing the risk of transmission infection. Another 
investigation showed that, during adult breath simulations 
by means of a piston pum, a commercially available filter 
attached to a nebulizer reduced exhaled aerosol droplets 
between 0.06 and 0.1 µm in size by 98% [21]. In summary, 
jet or mesh nebulisers should be used with a mouthpiece 
and a filter attached to the exhalation port of the nebuliser 
to reduce emission of exhaled aerosol droplets (Fig. 1). Care 
should be taken to ensure that the reservoir cap of the mesh 
nebuliser is closed after each use and the exhalation valve 
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of the mouthpiece is not blocked with the attachment of the 
filter to the mouthpiece. To avoid this problem, a silicon 
adaptor can be used between the filter and the mouthpiece 
of the mesh nebuliser.
Strategies to promote a safe and effective 
use of portable inhalers and nebulisers 
during SARS‑CoV‑2 pandemic
There is insufficient evidence on the risks associated with 
the transmission of SARS-CoV-2 during aerosol therapy. 
However, undertaking extra precautions to improve the 
safety and effectiveness of the aerosol delivery systems 
are essential during this global pandemic (Table 1). Ensur-
ing device safety and effectiveness depends on selecting 
the most appropriate device for each patient after careful 
evaluation of device features, the potential risk for device 
contamination and viral transmission. The pMDI should 
always be used in conjunction with a dedicated spacer or 
a valved-holding chamber (VHC) and not transferred from 
patient to patient. A mouthpiece should be preferred over 
a facemask when using spacers/VHCs; the latter should be 
cleaned and disinfected according to the manufacturer’s 
guidelines. Although not recommended, there are institu-
tions that employ the common canister protocol, which 
is a cost-saving strategy used in hospitals and clinics to 
deliver pMDI medications or to teach pMDI technique 
using a placebo pMDI [22]. In both scenarios, the pMDI is 
reused between patients, along with an individual spacer/
VHC. In these cases, hand hygiene and wiping the pMDI 
with 70% alcohol before and after use between patients are 
recommended [14]. Similarly, wiping the DPI mouthpiece 
off with a dry clean cloth, such as a paper towel, and proper 
storage are necessary [14]. Nebulisers should be disposed 
of, rinsed air dried washed and sterilised between treatments 
using liquid/hospital-grade disinfectants. Nebuliser acces-
sories can be cleaned and disinfected following manufac-
turer’s instructions or using agents such as isopropanol 70 
or hydrogen peroxide 3% [14]. The use of one-way valves 
and filters, particularly high-efficiency air filters, is recom-
mended with the nebulisers to minimise fugitive emissions 
and exposure of health care professionals (in hospital) and 
family members (at home) to aerosol medications. Finally, 
mouthpieces should be preferred while facemasks avoided 
as the delivery interface.
Conclusions
At present, evidence that nebulised treatment represents a 
risk for infection transmission is inconclusive due to the 
scarcity of information. Furthermore, there is no precedent 
to guide the treatment of patients with respiratory disease in 
the current situation. Although there is no evidence show-
ing that aerosols generated by nebulisers contain pathogens 
unless the nebuliser is contaminated, clinicians should exer-
cise caution with nebulisers and protect themselves from 
SARS-CoV-2 through a stringent sanitization protocol and 
the use of personal protective equipment during aerosol 
delivery to patients with known or suspected SARS-CoV-2 
infection. Therefore, it is vital to train patients and clini-
cians on the risk of contamination during device prepara-
tion and viral transmission while providing suggestions on 
how to use each device safely and effectively in patients 
with SARS-CoV-2 infection. If a patient takes precautions, 
such as nebuliser hygiene, avoidance of nebuliser use in the 
presence of other people, ensure that nebuliser use is done 
near open window or in areas with adequate ventilation, the 
possible risks for bystanders and health care personnel could 
be minimised.
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